TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24371021
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) 40 mg/day
Study: 24371021
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) 60 mg/day
Study: 24371021
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) 80 mg/day
Study: 24371021
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) (all doses combined)
Study: 22954329
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with locking plates for two-part fractures
Study: 22954329
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for two-part fractures
Study: 22954329
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with Philos locking plate for multi-fragmented fractures
Study: 22954329
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for multi-fragmented fractures
Study: 17700217
Drug: Gliclazide (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (G III)
Study: 17700217
Drug: Diet (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet (G IV)
Study: 17700217
Drug: Glibenclamide (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (G II)
Study: 17700217
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (G I)
Study: 11600559
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (5.8-6.5 mmol/liter)
Study: 11600559
Drug: Higher rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher rates of glucose infusion (up to 8.7 mmol/liter)
Study: 7947503
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment (10,000 i.u. initially, then 5000 i.u. twice weekly until miscarriage or the tenth week of pregnancy)
Study: 7947503
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment in women with follicular phase luteinising hormone > 10 iu/l
Study: 7947503
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment with clomiphene for ovulation induction
Study: 7947503
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in women with follicular phase luteinising hormone > 10 iu/l
Study: 2644594
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics after hospital discharge
Study: 2644594
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral antibiotics after hospital discharge
Study: 23291509
Drug: modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint-induced movement therapy followed by bimanual training (mCIMT-BiT)
Study: 16689010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-infective and symptomatic therapy only)
Study: 9869019
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg)
Study: 12658059
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lisinopril and nifedipine GITS
Study: 9024279
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) bolus and NS infusion
Study: 9024279
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NAL) bolus (4 mg) and NAL infusion (2 mg/h)
Study: 9024279
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) bolus and oCRH infusion (1 microgram/kg.h; maximum, 75 micrograms/h)
Study: 9024279
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NAL) bolus and both NAL and oCRH infusions
Study: 24450889
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy for 9 months
Study: 24450889
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no isoniazid preventive therapy)
Study: 24450889
Drug: Intervention clusters
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention clusters (mass screening and treatment)
Study: 22672970
Drug: 100mg/m² weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/m² weekly gemcitabine with 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks (Arm B)
Study: 19128941
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) trials
Study: 19128941
Drug: Patch trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch trials
Study: 19128941
Drug: Trials funded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials funded by the pharmaceutical industry
Study: 17496226
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy based on Fe(NO) measurements (n = 58)
Study: 17496226
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy based on Fe(NO) measurements
Study: 10926311
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg ALA orally per day over 6 weeks
Study: 10926311
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ALA intravenously over 15 minutes
Study: 1626957
Drug: Preoperative therapy-ACNU
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative therapy-ACNU
Study: 1626957
Drug: ACNU combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACNU combination group
Study: 6497641
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 1 mg/kg (Group 1)
Study: 6497641
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 1 mg/kg (Group 2)
Study: 6497641
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 4 mg/kg (Group 3)
Study: 27340931
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) supplementation at 4 g/day
Study: 20392399
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 microg, 4 hourly, maximum of 2 doses)
Study: 20392399
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (50 microg, 4 hourly, maximum of 2 doses)
Study: 27950588
Drug: Aggressive range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive range of motion (ROM) exercises with postural sensory therapy
Study: 27950588
Drug: Postural sensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postural sensory therapy alone (PS)
Study: 27950588
Drug: Both therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapy protocols
Study: 14570643
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% continuous infusion at 5 mL/h for up to 48 h after surgery
Study: 14570643
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% continuous infusion
Study: 10761161
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (EES) 200 mg given orally 10 minutes after i.m. treatments
Study: 10761161
Drug: Intramuscular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular saline (SAL, 0.5 ml), scopolamine (SCP, 0.1 mg), or promethazine (PMZ, 25 mg)
Study: 8883527
Drug: Iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol at 320 mg I/ml (IOD‐320)
Study: 8883527
Drug: Iohexol at
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol at 300 mg I/ml (IOH‐300)
Study: 26549402
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg/d)
Study: 19487925
Drug: Quifenadine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quifenadine (2 mg kg(‐1) day(‐1); n = 54)
Study: 19487925
Drug: Amiodarone (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (9 mg kg(‐1) day(‐1); n = 50)
Study: 15543591
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alpha‐2b induction (6 MU daily for 2 weeks) followed by 6 MU thrice weekly for 46 weeks (IFN/R group)
Study: 15543591
Drug: Pegylated IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated IFN alpha‐2b (1.5 microg/kg) weekly for 48 weeks in combination with ribavirin (600‐1,000 mg daily) (PEG/R group)
Study: 12784066
Drug: WEB 2086
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB 2086 gel (3%)
Study: 8777104
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 administered 2 min after maximum block (intense block group)
Study: 8777104
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 administered after 10% recovery of T1 (conventional reversal group)
Study: 8777104
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 (intense block group)
Study: 8777104
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 (conventional reversal group)
Study: 8777104
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 (spontaneous recovery group)
Study: 1802194
Drug: Aspirin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (180 mg daily) with fat-modified control diet
Study: 6185209
Drug: BLM‐MTX (bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLM‐MTX (bleomycin 30 mg intravenously twice weekly, methotrexate 25 mg intravenously twice weekly for 2 1/2 and two weeks, respectively)
Study: 6185209
Drug: CMF (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (methotrexate 25 mg twice weekly for two weeks, Cytoxan 100 mg/day for two weeks, 5‐FU 500 mg twice weekly for 1 1/2 weeks)
Study: 23670111
Drug: Attention-control treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control treatment, healthy lifestyle tips (HT)
Study: 19298338
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (duration 3 to 5 days)
Study: 19298338
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (duration 5 to 10 days)
Study: 11686818
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B 3D Plaque Remover D15
Study: 9215844
Drug: Urokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase with heparin (320 U/h)
Study: 29758039
Drug: Palonosetron (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.075 mg, intravenous)
Study: 27159993
Drug: Sativex(®) oral
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex(®) oral spray, up to 12 sprays/day for 12 weeks
Study: 27159993
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral spray, up to 12 sprays/day for 12 weeks
Study: 23579427
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (0.8 g/kg)
Study: 23579427
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol (0.4 g/kg)
Study: 23579427
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose and outcome expectancies
Study: 11202126
Drug: Unspecific supportive
Normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unspecific supportive control therapy
Study: 7492128
Drug: Topical emollients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical emollients (Control)
Study: 232697
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pivmecillinam four times daily for seven days
Study: 232697
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ampicillin four times daily for seven days
Study: 31727676
Drug: GX-188E injection
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-188E injection
Study: 25927321
Drug: Breezhaler (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breezhaler (single-dose inhaler)
Study: 21262317
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg caffeine
Study: 14644398
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg per day)
Study: 14644398
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg per day)
Study: 14644398
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae antibody positive patients
Study: 10723666
Drug: Single 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200 mg dose of levofloxacin (LVFX)
Study: 10723666
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of levofloxacin (LVFX) administered twice a day for three days
Study: 8160955
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 10 micrograms/ml with 0.1% bupivacaine (group FB)
Study: 8160955
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 10 micrograms/ml without bupivacaine (group F)
Study: 16595614
Drug: Gabapentin 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,600 mg
Study: 14609606
Drug: LDL cholesterol
Normalized name: LDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol <70 mg/dl
Study: 14609606
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with LDL cholesterol <100 mg/dl
Study: 8769601
Drug: RSHZ19 (0.025‐10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSHZ19 (0.025‐10.0 mg/kg)
Study: 8769601
Drug: RSHZ19 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSHZ19 (10 mg/kg)
Study: 8769601
Drug: RSHZ19 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSHZ19 (5 mg/kg)
Study: 8311368
Drug: Current smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current smoking (20 or more cigarettes daily)
Study: 8311368
Drug: Current smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current smoking (fewer than 20 cigarettes daily)
Study: 2905133
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg temazepam (Planum)
Study: 29697011
Drug: Vibratory vest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibratory vest therapy (Vest)
Study: 20964769
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone (40 mg·kg(‐1) rectal)
Study: 20964769
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and intranasal fentanyl (1 mcg·kg(‐1))
Study: 20964769
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and intramuscular ketorolac (1 mg·kg(‐1))
Study: 10740141
Drug: Candesartan (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (initial dosage 4 mg/d, increased to 16 mg/d if tolerated)
Study: 1376362
Drug: Buprenorphine (0.5-8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.5-8.0 mg)
Study: 6722464
Drug: Subcutaneous sphincterotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sphincterotomy
Study: 30043449
Drug: SQ house
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ house dust mite sublingual immunotherapy-tablet (10,000 JAU)
Study: 25280421
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate preparation at a dose of 3 capsules/d for a total zinc content of 150 mg/d (Z group)
Study: 22850072
Drug: Standard 4-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-drug therapy (Metronidazole 500 mg/BD, Amoxicillin 1g/BD, Omeprazole 20mg/BD, Bismuth 240 mg/BD) + Lycopene (30 mg/daily)
Study: 22850072
Drug: Standard 4-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-drug therapy (Metronidazole 500 mg/BD, Amoxicillin 1g/BD, Omeprazole 20mg/BD, Bismuth 240 mg/BD)
Study: 19549250
Drug: Insulin-glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glucose infusion therapy
Study: 7842769
Drug: Bambuterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (20 mg tablet) - morning administration
Study: 7842769
Drug: Bambuterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (20 mg tablet) - evening administration
Study: 2297349
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3.8 g of n-3 fatty acids)
Study: 24007456
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg once daily (qd)
Study: 24007456
Drug: Glimepiride 1-4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1-4 mg qd
Study: 15841998
Drug: Intranasal endoscopic
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal endoscopic sphenopalatine artery ligation (ESAL)
Study: 9402071
Drug: Nucleoside (zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside (zidovudine 600 mg/day and zalcitabine 2.25 mg/day)
Study: 31094746
Drug: Dextromethorphan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (30 mg)
Study: 3659583
Drug: Dextromethorphan +
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan + Salbutamol (30 mg + 2 mg)
Study: 27207493
Drug: Local cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cold gel pack
Study: 27207493
Drug: Local cold-hot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cold-hot gel pack
Study: 25049242
Drug: DHA-PQ with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-PQ with 8.5 g fat (group B)
Study: 22946930
Drug: i.v. ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ibandronate 3 mg every 3 months for 12 months
Study: 18940086
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to a radio transmission (oral medium)
Study: 12888874
Drug: Enoxaparin (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (subcutaneous, twice daily)
Study: 12888874
Drug: UFH (intravenous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (intravenous)
Study: 9368703
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acarbose plus 10 ml antacid suspension
Study: 9368703
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml antacid suspension
Study: 3887887
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g naturally labeled 13C carbohydrate after high fat antecedent diet
Study: 3887887
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g naturally labeled 13C carbohydrate after mixed antecedent diet
Study: 3887887
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g naturally labeled 13C carbohydrate after high carbohydrate antecedent diet
Study: 28738709
Drug: Nebulized hypertonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hypertonic saline solution (HSS) twice daily
Study: 27167367
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (standard care with traditional physical therapy)
Study: 25050903
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of ultrasound-guided laser ablation therapy (LAT) using a 1064nm Nd-YAG laser source at 3 W output power.
Study: 25050903
Drug: Follow-up with
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up with no treatment (Control group).
Study: 18705707
Drug: Above-median fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Above-median fluid intake (24 ml/kg/day)
Study: 18705707
Drug: Below-median fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Below-median fluid intake (16 ml/kg/day)